Pharmaceuticals Market Research Reports & Industry Analysis

Pharmaceuticals refer to compounds manufactured for use as a medicinal drug. Companies active in the pharmaceutical industry are involved in development, production and marketing of pharmaceuticals.

The global market for pharmaceuticals is demonstrating a substantial growth in Latin America and Asia, but is relatively stable in Europe. The worldwide market is assessed at about USD 300 billion yearly. The USA, Japan, Germany, France and China are the top pharmaceutical markets. The pharmaceutical industry benefits from the ageing population; new medical discoveries and new drugs approvals; the increased number of chronic, degenerative and heart diseases, and cancer.

The research reports of this Catalogue cover all the major categories within global, regional and local pharmaceuticals markets. The reports offer overviews of the market trends, drivers; factors contributing to market growth. The challenges faced by industry participants, analyses of the top companies involved in the marketplace, and the key market news are provided in the reports.

Found 14465 publications
Ebola Virus Vaccine Market & Pipeline Insight US$ 1,500.00

... has been met till now. The pharma companies have a significant opportunity in the field of Ebola virus infections in terms of developing drugs, ... return on investment. “Ebola Virus Vaccine Market & Pipeline Insight” Report Highlight: Ebola Virus Infection Market Overview Ebola Vaccine Clinical Trial ...

Oct, 2014 80 pages
Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins US$ 255.00

Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins The present Competitive Intelligence Report about prophylaxis and therapy of Rabies ... virus infections as of September 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any ...

Sep, 2014 33 pages
Competitor Analysis: Ebola Virus Vaccines and Therapeutics US$ 255.00

Competitor Analysis: Ebola Virus Vaccines and Therapeutics The present Competitive Intelligence Report about prophylaxis and therapy of Ebola virus infections ... Ebola virus infections as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any ...

Oct, 2014 43 pages
Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition) US$ 1,495.00 US$ 1,270.75

... development time and budget. Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices ... set of full text in English of the latest Chinese applicable regulations for medical device clinical evaluation and clinical trial of imported overseas ...

Oct, 2014 199 pages
Orphan Drug Market Access: Payer Insights on the Present and Future US$ 495.00

... stakeholders have valid interests which have to be addressed now. Orphan Drug Market Access: Payer Insights on the Present and Future offers insights ... cost, clinical data and involvement in the research process? Which future market developments may pose challenges? (ie: risk sharing, HTA assessment, a less ...

Oct, 2014
Physician Views: Can Portola's reversal agent act as growth catalyst for novel anticoagulants? US$ 645.00

... but whom subsequently need the anticoagulant action to be reversed due to bleeding or the requirement for surgery. Portola's assertion that andexanet alfa will ... catalyst that could increase usage of the Factor Xa class, with Portola successfully leveraging this dynamic to secure co-funding for its clinical ...

Oct, 2014
NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2014 US$ 1,500.00

... , key information and facts, and its locations and subsidiaries The report reviews current pipeline of NAL Pharmaceuticals Ltd.’s human therapeutic ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the NAL Pharmaceuticals Ltd.’s pipeline products Reasons to ...

Sep, 2014 41 pages
Histocell S.L. - Product Pipeline Review - 2014 US$ 1,500.00

Summary Global Markets Direct’s, ‘Histocell S.L. - Product Pipeline Review - 2014’, provides an overview of the Histocell S.L.’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Histocell S.L.’s, complete ...

Sep, 2014 23 pages
Debiopharm International S.A. - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Debiopharm International S.A.’s pipeline products ...

Sep, 2014 61 pages
Beijing Minhai Biotechnology Co., Ltd - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Beijing Minhai Biotechnology Co., Ltd’s pipeline products ...

Sep, 2014 43 pages
Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020 US$ 2,625.00

... drug candidate for EVD. Both these companies are developing their anti-ebola products under the contract of the U.S. department of defense (DoD). ... held in past years concerning the development of ebola viral disease therapeutics Pin-point analysis of geographic segments helps to identify opportunities for ...

Sep, 2014 55 pages
Clinical Trails Market in India - 2014 US$ 4,000.00

This report provides an insight into the Clinical Trails current market scenario, structure and practices in India. In depth market scenario includes: ... Areas Providing insights into Industry drivers and challenges and their impact on the future market Regulatory bodies and their roles Future Market ...

Oct, 2014 35 pages
Pharmaceutical Business Confidence Report Q3 2014 US$ 1,950.00

Summary 'Pharmaceutical Business Confidence Report Q3 2014” is a new report by Kable that globally analyzes industry opinions on the latest economic and customer ... prospects over July–September 2014. The report provides information on the impact consumer confidence, supplier prices, and staff headcount are ...

Oct, 2014 60 pages
2014 Market Research Report on Global IVIG Industry US$ 3,600.00

2014 Market Research Report on Global IVIG Industry was professional and depth research report on Global IVIG industry. The report firstly introduced IVIG ... report also listed North America Europe Asia Rest of World regional 2009-2014 IVIG consumption and different regions trading business and regional import ...

Oct, 2014 208 pages
Sudan Pharmaceuticals and Healthcare Report Q4 2014 US$ 1,295.00

Includes 3 FREE quarterly updates BMI View: The pharmaceutical and healthcare markets of Sudan and South Sudan are forecast to see double-digit growth ... currency terms and -9.6% in US dollar terms. Forecast revised downwards from Q314. Healthcare: SDG19.2bn (USD4.11bn) in 2013 to SDG21.9bn (USD3.58bn) in ...

Oct, 2014 59 pages
Patient Assistance Programs: Payer and Pharma Perspectives US$ 495.00

... resistant and critical of the new PAP schemes. FirstWord’s Patient Assistance Programs: Payer and Pharma Perspectives report offers an insightful and ... Get Answers to Critical Questions What factors would positively influence payer attitudes towards PAPs? As formularies become more restrictive, what does ...

Oct, 2014
Top 50 Big Pharma Partnering and M&A Deal Trends US$ 3,295.00

... interests and activity of the worlds leading fifty big pharma companies. Top 50 Big Pharma Partnering and M&A Deal Trends provides the user with the ... to the report, whilst chapter 2 lists the top 50 leading big pharma companies based on 2013 pharmaceutical revenues and dealmaking activity since 2009. ...

Oct, 2014 816 pages
Salix Pharmaceuticals Partnering 2009-2014 US$ 995.00

... Agreements with Salix Pharmaceuticals 2009-2014 report provides an in-depth insight into the partnering interests and activities of one of the worlds ... 2 lists the top 50 leading big biotech companies based on 2013 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview ...

Sep, 2014 100 pages
Regenerative Medicine Partnering Terms and Agreements US$ 2,995.00

... royalty terms. Chapter 3 provides a review of the leading regenerative medicine deals since 2009. Deals are listed by headline value, signed by big pharma ... detailed review of all regenerative medicine partnering deals including cell therapy, organ regeneration, stem cells and tissue regeneration signed and ...

Oct, 2014 1116 pages
Pharmacyclics Partnering 2009-2014 US$ 995.00

... Agreements with Pharmacyclics 2009-2014 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading ... 2 lists the top 50 leading big biotech companies based on 2013 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview ...

Sep, 2014 100 pages
Jazz Pharmaceuticals Partnering 2009-2014 US$ 995.00

... Agreements with Jazz Pharmaceuticals 2009-2014 report provides an in-depth insight into the partnering interests and activities of one of the worlds ... 2 lists the top 50 leading big biotech companies based on 2013 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview ...

Sep, 2014 100 pages
Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics US$ 1,995.00

... will have a significant impact on each party’s ability to derive value from the deal. Report scope Global Joint Venture Partnerships in Pharma, ... dealmakers since 2009 The leading joint venture partnering resources In Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics, the available ...

Oct, 2014 652 pages
Pediatric Drugs Markets in China US$ 4,000.00

China's demand for pediatric drugs has grown at a fast pace in the past decade. In the next five years, both production and demand ... environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and ...

Apr, 2013 194 pages
Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, Mass Spectrometry, MALDI-TOF), Kits, and Reagents], Application... US$ 4,650.00

... this diversity. This report segment the global glycomics market by application, end users, products, and geographies. The application segments included ... report also provides a competitive landscape of the glycomics enzymes, instruments, kits and reagents market. The competitive landscape covers the growth ...

Sep, 2014 198 pages
Norway Pharmaceuticals and Healthcare Report Q4 2014 US$ 1,295.00

... as a result of the much lower cost of generics. Headline Expenditure Projections Pharmaceuticals: NOK19.90bn (USD3.36bn) in 2013 to NOK20.28bn (USD3.29bn) ... terms. Healthcare: NOK272.01bn (USD45.97bn) in 2013 to DKK280.88bn (USD45.62bn) in 2014; +3.3% in local currency terms. Risk/Reward Rating Norway ...

Oct, 2014 65 pages
Thrombophlebitis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Summary GlobalData's clinical trial report, “Thrombophlebitis Global Clinical Trials Review, H2, 2014' provides data on the Thrombophlebitis clinical trial scenario. This ... and many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities ...

Sep, 2014 84 pages
Telangiectasis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... 2014 Summary GlobalData's clinical trial report, “Telangiectasis Global Clinical Trials Review, H2, 2014' provides data on the Telangiectasis clinical trial scenario. This ... and many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities ...

Sep, 2014 52 pages
Systolic Hypertension Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Systolic Hypertension. It includes an overview of the trial numbers and their recruitment status as per the ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 98 pages
Supraventricular Tachycardia Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Supraventricular Tachycardia. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Sep, 2014 55 pages
Stable Angina Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Stable Angina. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Sep, 2014 74 pages
Renal Artery Stenosis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Review, H2, 2014' provides data on the Renal Artery Stenosis clinical trial scenario. This report provides elemental information and data relating ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 67 pages
Refractory Angina Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Refractory Angina. It includes an overview of the trial numbers and their recruitment status as per the ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Sep, 2014 53 pages
Pulmonary Valve Stenosis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Review, H2, 2014' provides data on the Pulmonary Valve Stenosis clinical trial scenario. This report provides elemental information and data relating ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 49 pages
Peripheral Artery Occlusive Disease (PAOD) Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Review, H2, 2014' provides data on the Peripheral Artery Occlusive Disease (PAOD) clinical trial scenario. This report provides elemental information and ... trials on Peripheral Artery Occlusive Disease (PAOD). It includes an overview of the trial numbers and their recruitment status as per the site of trial ...

Sep, 2014 85 pages
Fibrinogen Deficiency (Factor I deficiency) Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Review, H2, 2014' provides data on the Fibrinogen Deficiency (Factor I Deficiency) clinical trial scenario. This report provides elemental information and data ... in each, along with the clinical trial scenario in BRIC nations Clinical trial (complete and in progress) data by phase, trial status, subjects ...

Sep, 2014 60 pages
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Israel US$ 1,995.00

... Landscape - Israel Summary GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Israel”. The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape ...

Oct, 2014 234 pages
China Pharmaceutical Mfg. Industry Data Report US$ 580.00

This data report provides key statistics and concise analysis on pharmaceutical mfg. industry in China. It presents an overview on pharmaceutical mfg. industry's overall performance for the year 2011 to 2013, and reveals differences in various regions of Mainland China in terms of pharmaceutical mfg. sector, ...

Sep, 2014 29 pages
ICT investment trends in pharmaceuticals - Enterprise ICT spending patterns through to the end of 2015 US$ 2,995.00

... budgets across the core areas of enterprise ICT expenditure: hardware, software, IT services, communications, and consulting. The report illustrates the core technologies enterprises are investing in, including business intelligence, content management, and cloud computing. The survey also highlights the ...

Sep, 2014 57 pages
PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022 US$ 10,995.00

PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022 SUMMARY Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and ... pain market? What differences exist in the current disease management across the 3 NP indications, and across the 7 markets? What are the ...

Apr, 2014 423 pages
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023 US$ 10,995.00

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023 SUMMARY Major depressive disorder (MDD) is one of the most ... 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries ...

May, 2014 322 pages
PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update US$ 10,995.00

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update SUMMARY Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience ...

May, 2014 381 pages
PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update US$ 10,995.00

PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update SUMMARY Epilepsy is a brain disorder characterized by spontaneously occurring ... . Additional unmet needs still exists in terms of safety and efficacy. Will the drugs under development fulfil the unmet needs of the ...

Dec, 2013 306 pages
PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023 US$ 4,995.00

PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023 SUMMARY Asthma accounts for approximately 250,000 deaths around the world ... impact of key events as well the drivers and restraints affecting the US Asthma market. REASONS TO BUY Understand and capitalize by identifying products that ...

Aug, 2014 168 pages
PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023 US$ 4,995.00

PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023 SUMMARY Asthma accounts for approximately 250,000 deaths around the ... treatment with the ICS and ICS/LABA therapies. SCOPE Overview of Asthma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines ...

Aug, 2014 167 pages
PharmaPoint: Asthma - Current and Future Players US$ 2,995.00

... Future Players SUMMARY GlobalData has released its pharma report, “PharmaPoint: Asthma - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Asthma Market. The report identifies and analyses the key companies ...

Aug, 2014 55 pages
PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023 US$ 4,995.00

PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023 SUMMARY Asthma accounts for approximately 250,000 deaths around the world ... , this growth will be fueled mainly by the uptake of the new branded biologic drugs. A dip in sales caused by the Singulair patent expiry in 2012, as well as ...

Aug, 2014 183 pages
PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023 US$ 6,995.00

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023 SUMMARY Asthma accounts for approximately 250,000 deaths around the ... the French, Spanish, and UK markets is attributable to the slightly decreasing prevalence of asthma in this country over the forecast period. . Advair’s active patent on ...

Aug, 2014 218 pages
Cough, Cold and Allergy (Hay Fever) Remedies in Algeria US$ 900.00

Rising disposable income levels supported sales growth in cough, cold and allergy (hay fever) remedies towards the end of the review ... domestic production struggling to meet demand. Euromonitor International's Cough, Cold and Allergy (Hay Fever) Remedies in Algeria report offers a comprehensive guide to the ...

Sep, 2014 23 pages
Thermalin Diabetes, LLC - Product Pipeline Review - 2014 US$ 1,500.00

... , key information and facts, and its locations and subsidiaries The report reviews current pipeline of Thermalin Diabetes, LLC’s human therapeutic ... dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Thermalin Diabetes, LLC’s pipeline products Reasons ...

Sep, 2014 26 pages
tesa Labtec GmbH - Product Pipeline Review - 2014 US$ 1,500.00

... stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the tesa Labtec GmbH’s pipeline products Reasons ...

Sep, 2014 22 pages
1 2 3 4 5 >
Skip to top